📈 2-year data from the Phase 3 SURPASS-ET trial presented at #SOHO2026 shows continuous ropeginterferon alfa-2b (ropeg) delivers durable hematologic & molecular benefits for high-risk essential thrombocythemia!
More details: https://bit.ly/3TodPwU
@hematologyadvisor.bsky.social
